- Earth
Science Tech offers biotech expertise in the largest sector of the legal
cannabis market
- The
CBD market is projected to see 700 percent growth through 2019
- ETST’s
portfolio is designed to further establish its position in the burgeoning
sector
Earth Science Tech Inc. (OTCQB: ETST) is an innovative
biotechnology company operating in the fields of hemp cannabinoid,
nutraceutical, pharmaceutical and medical device research and development. With
biotech being the largest sector of the legal cannabis market (http://ibn.fm/Jx6JA), ETST
appears ideally poised to be a key player in the burgeoning space.
Brightfield Group, a leading market and consumer
intelligence firm for the legal cannabinoids and cannabis industries, recently
reported that the U.S. CBD market was projected to see an unprecedented 700
percent growth through 2019 (http://ibn.fm/YHh0w).
With hemp-derived CBD increasingly being used in health, wellness and
anti-pharma products, the market is actually estimated to reach $23.7 billion
by 2023.
Biotech researchers are committed to uncovering innovative
new ways that CBD can be used for medicinal and other purposes. ETST recognizes
the opportunity and is leveraging its background and expertise in both biotech
and cannabis to firmly establish its position in the space. As part of that
strategy, the company is widening its reach through strategic partnerships
designed to develop new and novel cannabinoid-based pharmaceutical and
nutraceutical products.
Included in Earth Science Tech’s portfolio are three wholly
owned subsidiaries focused on expanding the company’s work in the
pharmaceutical and medical device sectors. These subsidiaries include Cannabis
Therapeutics Inc., KannaBidioiD (“KBD”) and Earth Science Pharma.
Cannabis Therapeutics Inc. is leading out in the development
of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical
products. CTI is invested in research and development to explore and harness
the medicinal power of cannabidiol. The company holds a provisional application
patent for a CBD product that is focused on developing treatments for breast
and ovarian cancers.
KannaBidioiD provides a variety of products designed for the
recreational cannabis arena. KBD’s unique Kanna and CBD formulation is sold and
distributed in CBD-infused edibles and e-liquid products.
Earth Science Pharma Inc. is committed to the development of
low-cost, noninvasive diagnostic tools, medical devices, testing processes and
vaccines for sexually transmitted infections and/or diseases. The company’s
first medical device, MSN-2, is a home kit designed for the detection of STIs,
such as chlamydia, from a self-obtained gynecological specimen. Earth Science
Pharma is working to develop and bring to market medical devices and vaccines
that meet the specific needs of women.
Earth Science Tech’s current and pipeline offerings provide
a variety of products and unique formulations. As legalization of medical
marijuana spreads, investment opportunities in the cannabis biotech sector
continue to grow.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates
relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
